The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJena University Hospital

About this trial

Here, the investigators propose to study host responses to reduced microbiome complexity driven by treatment with broad spectrum antibiotics in patients with severe infections or sepsis. The proposal aims to combine holistic approaches with emerging experimental technologies to investigate the complex interactions between the gut microbiota and its host and assess the impact of specific bacterial communities on longevity and stress responses. A strong focus of this study will also be placed on microbiome dysbiosis and secondary impacts on short- and long-term brain dysfunction using clinical, laboratory and imaging procedures.

Eligibility criteria

Qualifiers

Age ≥ 18 years

One of the following criteria

Critically ill patients treated with meropenem or piperacillin/tazobactam started within the last 72 h

Critically ill patients without systemic antimicrobial therapy within the last 72 hours and an expected ICU length of stay of more than 3 days

Disqualifiers

Inflammatory bowel disease

Major bowel resection

Selective decontamination of the oral and digestive tract

Oral vancomycin therapy

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

100 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Jena University Hospital

Lead sponsor

University of Jena

Collaborator